Open Access<p>Response to Anti-HER2-Based Treatment in a Patient with Bladder Adenocarcinoma Harboring <em>HER2</em> Amplification and S310F Mutation Discovered by Next-Generation Sequencing: A Case Report</p>
Author(s) -
Xiaolu Wang,
Weixin Hu,
Li Xie
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s247515
Subject(s) - trastuzumab , medicine , adenocarcinoma , oncology , bladder cancer , targeted therapy , mutation , dna sequencing , metastasis , cancer research , cancer , gene , biology , breast cancer , biochemistry
HER2 overexpression has been identified in approximately 14% of bladder adenocarcinomas. However, until now, there has been no approved standard targeted therapy for bladder adenocarcinoma patients harboring HER2 genetic alteration.